Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty
Primary Purpose
Bleeding Reduction
Status
Unknown status
Phase
Phase 4
Locations
Poland
Study Type
Interventional
Intervention
Tranexamic Acid
Tranexamic Acid
Sodium Chloride
Sponsored by
About this trial
This is an interventional supportive care trial for Bleeding Reduction focused on measuring tranexamic acid, rhinoplasty, bleeding reduction
Eligibility Criteria
Inclusion Criteria:
- age > 18 y.o.
- American Society of Anesthesiologists Physical Status Classification (ASA) 1-2
- signed informed consent form after reading the information about the study and talking with one of the investigators
Exclusion Criteria:
- pregnancy
- known allergies for tranexamic acid or any other substance in Exacyl
- deep vein thrombosis
- Hormone Replacement Therapy or oral contraceptive usage
- anticoagulants usage
- obesity - BMI (body mass index) >30 kg/m2
- renal disease, as glomerular filtration rate (GFR) <60 ml/min/1,73 m*m
- seizures or epilepsy in the past
Sites / Locations
- Samodzielny Publiczny Szpital Kliniczny im. prof. W. Orłowskiego w WarszawieRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Very low dose
Low dose
Arm Description
Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
Outcomes
Primary Outcome Measures
Intraoperational bleeding
it would be assessed at the end of the surgery by measuring blood volume in the suction device and net weight of all surgical material. (precision balance - 2 mg)
Secondary Outcome Measures
Adverse effects
any adverse effects connected with tranexamic acid usage would be noted
surgical field assesment
Fromm scale of surgical field would be used
surgery length
surgical procedure length would be noted
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03070847
Brief Title
Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty
Official Title
Impact of Prophylactic Tranexamic Acid on Intra and Postoperational Bleeding Reduction in Patients Undergoing Rhinoplasty Surgery. Low (10mg/kg) and Very Low (5mg/kg) Dose Comparison
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
March 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Bartłomiej Wódarski
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether very low dose of preoperative tranexamic acid (5mg/kg) is as effective as low dose (10mg/kg) for intraoperational bleeding reduction in patients undergoing elective rhinoplasty surgery.
Detailed Description
Background
Tranexamic acid is a drug registered for bleeding prevention and reduction. It is on the World Health Organisation (WHO) 'essential drugs list'. Preoperative tranexamic acid efficacy is well proved for doses between 10 and 40 mg/kg and last years and decades publications showed that 'low dose' (10mg/kg) is as efficient as higher doses but connected with less adverse effects.
Objectives
To determine whether 5 mg/kg dose is as effective as commonly used 10mg/kg dose in intraoperational bleeding reduction.
Methodology All patients would be randomised into one of two arms - low and very low dose. Patients, investigators and caregivers would be blinded. Patients would receive intravenous bolus of tranexamic acid at 15 minutes before admission to operation theatre in a dose dependent on the study arm. General, intravenous anesthesia (total intravenous anesthesia) would be performed due to hospital standards. At the end of the surgery total blood volume and adverse effects would be noted. Surgeon would asses surgical field in the Fromm scale.
The survey is planned for a two years timespan or until 50 patients have enrolled (25 for each arm).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bleeding Reduction
Keywords
tranexamic acid, rhinoplasty, bleeding reduction
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Blinded (participant, care provider, investigator). Computer block randomisation tool will be used (randomisation.com 1 block, 50 subjects per block), 50 notes with '5 mg/kg' or '10 mg/kg' will be put into sealed envelopes.
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Very low dose
Arm Type
Experimental
Arm Description
Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
Arm Title
Low dose
Arm Type
Active Comparator
Arm Description
Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
Exacyl
Intervention Description
Dose: 5mg/kg
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Other Intervention Name(s)
Exacyl
Intervention Description
Dose: 10mg/kg
Intervention Type
Drug
Intervention Name(s)
Sodium Chloride
Intervention Description
Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
Primary Outcome Measure Information:
Title
Intraoperational bleeding
Description
it would be assessed at the end of the surgery by measuring blood volume in the suction device and net weight of all surgical material. (precision balance - 2 mg)
Time Frame
during rhinoplasty
Secondary Outcome Measure Information:
Title
Adverse effects
Description
any adverse effects connected with tranexamic acid usage would be noted
Time Frame
during rhinoplasty and first day after surgery
Title
surgical field assesment
Description
Fromm scale of surgical field would be used
Time Frame
during rhinoplasty
Title
surgery length
Description
surgical procedure length would be noted
Time Frame
during rhinoplasty
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
age > 18 y.o.
American Society of Anesthesiologists Physical Status Classification (ASA) 1-2
signed informed consent form after reading the information about the study and talking with one of the investigators
Exclusion Criteria:
pregnancy
known allergies for tranexamic acid or any other substance in Exacyl
deep vein thrombosis
Hormone Replacement Therapy or oral contraceptive usage
anticoagulants usage
obesity - BMI (body mass index) >30 kg/m2
renal disease, as glomerular filtration rate (GFR) <60 ml/min/1,73 m*m
seizures or epilepsy in the past
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bartłomiej Wódarski, MD
Phone
505064789
Email
barwoda@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Paweł Krzęczko, MD
Email
pawkrze@o2.pl
Facility Information:
Facility Name
Samodzielny Publiczny Szpital Kliniczny im. prof. W. Orłowskiego w Warszawie
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
00-416
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bartłomiej Wódarski, MD
Phone
505064789
Email
barwoda@gmail.com
First Name & Middle Initial & Last Name & Degree
Paweł Krzęczko, MD
Email
pawkrze@o2.pl
First Name & Middle Initial & Last Name & Degree
Paweł Krzęczko, MD
First Name & Middle Initial & Last Name & Degree
Kamil Radzikowski, MD
First Name & Middle Initial & Last Name & Degree
Małgorzata Malec-Milewska, MD, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty
We'll reach out to this number within 24 hrs